People: GenVec Inc (GNVC.OQ)

GNVC.OQ on NASDAQ Stock Exchange Capital Market

2.07USD
19 Sep 2014
Price Change (% chg)

$-0.10 (-4.61%)
Prev Close
$2.17
Open
$2.20
Day's High
$2.23
Day's Low
$2.07
Volume
70,021
Avg. Vol
8,092
52-wk High
$4.25
52-wk Low
$0.73

Search Stocks

Summary

Name Age Since Current Position

Wayne Hockmeyer

69 2013 Chairman of the Board

Douglas Swirsky

44 2013 President, Chief Executive Officer, Director

Bryan Butman

60 2012 Senior Vice President - Development

Douglas Brough

58 Vice President - Head of Research

Zola Horovitz

79 2013 Director

Stefan Loren

49 2013 Director

William Kelley

74 2002 Independent Director

Marc Schneebaum

59 2007 Independent Director

Rena Cohen

2013 IR Contact Officer

Biographies

Name Description

Wayne Hockmeyer

Dr. Wayne T. Hockmeyer, Ph.D., is Chairman of the Board of Genvec, Inc. Dr. Hockmeyer founded MedImmune, Inc. (“MedImmune”) in April 1988 as President and Chief Executive Officer and was elected a director of MedImmune in May 1988. Dr. Hockmeyer became Chairman of the board of directors of MedImmune in May 1993 and left his position as Chief Executive Officer in October 2000. Dr. Hockmeyer is currently retired, having resigned from his positions as a member of the MedImmune board of directors and as President of MedImmune Ventures, Inc. following the acquisition of MedImmune by AstraZeneca Biopharmaceuticals, Inc. in June 2007. Dr. Hockmeyer earned his bachelor’s degree from Purdue University and his Ph.D. from the University of Florida in 1972. Currently, he is a director of Baxter International Inc. and Idenix Pharmaceuticals, Inc. Within the past five years, Dr. Hockmeyer has also served on the board of Middlebrook Pharmaceuticals, Inc.

Douglas Swirsky

Mr. Douglas J. Swirsky is President, Chief Executive Officer, Director of GenVec, Inc. He joined the Company in 2006 as Chief Financial Officer, Corporate Secretary and Treasurer, which are positions he continues to hold. Prior to joining the Company, Mr. Swirsky was a Managing Director and the Head of Life Sciences Investment Banking at Stifel Nicolaus from 2005 to 2006 and held investment banking positions at Legg Mason from 2002 until Stifel Financial’s acquisition of the Legg Mason Capital Markets business in 2005. Mr. Swirsky, a Certified Public Accountant and holder of a Chartered Financial Analyst® designation, previously held investment banking positions at UBS, PaineWebber, and Morgan Stanley. His experience also includes positions in public accounting and consulting. Mr. Swirsky received his undergraduate degree in Business Administration from Boston University and his M.B.A. from the Kellogg School of Management at Northwestern University. Mr. Swirsky is a member of the Board of Directors of Fibrocell Science, Inc. Within the past five years, Mr. Swirsky has also served on the board of PolyMedix, Inc.of Fibrocell Science, Inc.

Bryan Butman

Dr. Bryan T. Butman, Ph.D., is Senior Vice President of Development of GenVec, Inc. He joined GenVec in 1999 and previously served as Director of Quality and Analytical Sciences from 1999 to 2002, Vice President of Quality from 2002 to 2005, Vice President of Vector Operations from 2005 to 2006 and Senior Vice President of Vector Operations from 2006 to 2012. Prior to joining GenVec, Dr. Butman was Executive Director of Diagnostic Product Research and Development with INTRACEL Corporation, a biotechnology company that originated from AKZO-Nobel, NV. During his 15-year career with INTRACEL, Dr. Butman developed FDA-regulated products in the areas of oncology, infectious disease, cardiovascular disease, and hematology, as well as AOAC approved products to monitor food safety. He began his product development career in 1983 as a Senior Scientist with Warner-Lambert, Co. Dr. Butman holds a Ph.D. in Biological Sciences from Wayne State University (Detroit, MI).

Douglas Brough

Dr. Douglas E. Brough, Ph.D., is Vice President - Head of Research of GenVec Inc. Dr. Brough has held several positions at GenVec including Vice President, Head of Research, Executive Director of Vector Sciences, Senior Director of Vector Sciences, Director of Vector Sciences, Director of Molecular Virology, Head Molecular Virology and Research Scientist. Prior to joining GenVec, Dr. Brough was a Research Fellow in the Department of Molecular Biology at the Lewis Thomas Laboratory, Princeton University. Dr. Brough received his B.S. in Biology from Purdue University, a M.S. in Microbiology and Biochemistry from Idaho State University and his Ph.D. in Microbiology and Molecular Genetics from Rutgers, the State University of New Jersey and the Robert Wood Johnson Medical School. Dr. Brough performed post-doctoral research in molecular biology at Princeton University.

Zola Horovitz

Dr. Zola P. Horovitz, Ph.D., is Director of Genvec, Inc. Dr. Horovitz is currently retired. Dr. Horovitz is a member of the Nominating and Corporate Governance Committee and the Audit Committee and is the Chairman of the Board of Directors. Dr. Horovitz is currently retired. He served as a director of Diacrin, Inc. from 1994 to August 2003. From 1991 to 1994, Dr. Horovitz was Vice President, Business Development and Planning at Bristol-Myers Squibb Pharmaceutical Group and was Vice President, Licensing from 1989 to 1991. Prior to 1989, Dr. Horovitz spent 30 years as a member of the Squibb Institute for Medical Research and received his Ph.D. from the University of Pittsburgh. Dr. Horovitz currently serves as a director of Palatin Technologies, Inc. Within the past five years, Dr. Horovitz also served on the boards of BioCryst Pharmaceuticals, Inc., Genaera Corp, NitroMed, Inc., Avigen, Inc. and DoV Pharmaceutical Inc.

Stefan Loren

Dr. Stefan F. Loren, Ph.D., has been appointed as Director of GenVec, Inc., effective September 19, 2013. Dr. Loren is a member of the Audit Committee. Dr. Loren was recommended to the Nominating and Corporate Governance Committee by a stockholder of the Company, based on his experience in both financial markets and biotechnology research and development. Dr. Loren is a Managing Director of Westwicke Partners, a healthcare-focused consulting firm, a position he has held since 2008. From 2007 to 2008, Dr. Loren was an Analyst with Perceptive Advisors, a healthcare-focused investment fund, and, prior to that, served as an analyst and portfolio manager for MTB Investment Advisors from 2005 to 2007. Prior to 2005, Dr. Loren was a Managing Director in the healthcare equity research group at Legg Mason, and before joining Legg Mason, a Research Chemist at the advanced technologies division of Abbott Laboratories and a Research Fellow at the Scripps Research Institute. Dr. Loren received his B.A. from the University of California, San Diego, and his Ph.D. from University of California, Berkeley. Currently, he is a director of Marina Biotech, Inc. Within the past five years, Dr. Loren has served on the boards of directors of Orchid Cellmark Inc. and Polymedix, Inc.

William Kelley

Dr. William N. Kelley, M.D., is Independent Director of Genvec, Inc. Dr. Kelley is the Chairman of the Nominating and Corporate Governance Committee and a member of the Compensation Committee. Dr. Kelley and his colleagues at the University of Michigan were the first to propose in vivo gene therapy as it is recognized today and the first to directly administer a human gene in vivo and obtain expression in an experimental animal model. From 1989 to 2000, Dr. Kelley served as Executive Vice President of the University of Pennsylvania with responsibilities as Chief Executive Officer for the Medical Center, Dean of the School of Medicine, and the Robert G. Dunlop Professor of Medicine and Biochemistry and Biophysics. He is currently Professor of Medicine and Professor of Biochemistry and Biophysics at the School of Medicine of the University of Pennsylvania. In the national leadership arena, Dr. Kelley has served as President of the American Society for Clinical Investigation, President of the American College of Rheumatology, Chair of the American Board of Internal Medicine, and Chair of the Residency Review Committee for Internal Medicine. Within the past five years, Dr. Kelley served on the board of directors of Merck & Co. Inc., Beckman Coulter, Inc., Advanced Biosurfaces, Inc. and Polymedix, Inc.

Marc Schneebaum

Mr. Marc R. Schneebaum is Independent Director of Genvec, Inc. Mr. Schneebaum is a member of the Compensation Committee and the Chairman of the Audit Committee. Mr. Schneebaum served as President, Chief Executive Officer and a director of Predictive BioSciences, Inc., a commercial stage cancer diagnostics company, from 2011 to 2013. From 1997 to 2010, Mr. Schneebaum served as President, Chief Executive Officer, and a director of Sensors for Medicine and Science, Inc., an emerging medical technology company. From 1991 to 1997, he served as Senior Vice President, Finance, Business Development and Administration, and Chief Financial Officer of Genetic Therapy, Inc., a biotechnology company (acquired by Sandoz / Novartis). From 1987 to 1991, Mr. Schneebaum was a Vice President at Alex Brown & Sons Incorporated, a leading investment banking firm (now part of Deutsche Bank), where he participated in a variety of finance and strategic assignments. Mr. Schneebaum began his career in the accounting and auditing group at KPMG LLP, advancing to Senior Manager in the management consulting group. Mr. Schneebaum, a Certified Public Accountant (inactive), received his degree in Business Administration from the University of Maryland. He has also served on the boards of the March of Dimes of Maryland and the Maryland Enterprise Investment Fund.

Rena Cohen

Basic Compensation

Name Fiscal Year Total

Wayne Hockmeyer

--

Douglas Swirsky

528,115

Bryan Butman

395,804

Douglas Brough

453,866

Zola Horovitz

--

Stefan Loren

--

William Kelley

--

Marc Schneebaum

--

Rena Cohen

--
As Of 30 Dec 2013

Options Compensation

Search Stocks